INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 290 filers reported holding INTRA CELLULAR THERAPIES INC in Q3 2023. The put-call ratio across all filers is 1.03 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $71,227,000 | +10.5% | 1,367,375 | +34.3% | 0.09% | +20.3% |
| Q2 2023 | $64,485,000 | +164.6% | 1,018,397 | +126.3% | 0.07% | +155.2% |
| Q1 2023 | $24,368,000 | +2.3% | 450,000 | 0.0% | 0.03% | +3.6% |
| Q4 2022 | $23,814,000 | +13.0% | 450,000 | -0.4% | 0.03% | +7.7% |
| Q3 2022 | $21,079,000 | -29.8% | 451,920 | -14.1% | 0.03% | -23.5% |
| Q2 2022 | $30,022,000 | +8.5% | 525,973 | +16.3% | 0.03% | +61.9% |
| Q1 2022 | $27,669,000 | +17.1% | 452,172 | +0.2% | 0.02% | +5.0% |
| Q4 2021 | $23,628,000 | +40.4% | 451,441 | 0.0% | 0.02% | +42.9% |
| Q3 2021 | $16,830,000 | -8.7% | 451,441 | 0.0% | 0.01% | -6.7% |
| Q2 2021 | $18,428,000 | +20.1% | 451,441 | -0.2% | 0.02% | -31.8% |
| Q1 2021 | $15,342,000 | +6.5% | 452,164 | -0.2% | 0.02% | +4.8% |
| Q4 2020 | $14,402,000 | +23.9% | 452,890 | 0.0% | 0.02% | +5.0% |
| Q3 2020 | $11,621,000 | +60.0% | 452,890 | +60.1% | 0.02% | +53.8% |
| Q2 2020 | $7,262,000 | +101.1% | 282,890 | +20.4% | 0.01% | +85.7% |
| Q1 2020 | $3,612,000 | +5.3% | 235,000 | +135.0% | 0.01% | +40.0% |
| Q4 2019 | $3,431,000 | +359.3% | 100,000 | 0.0% | 0.01% | +400.0% |
| Q3 2019 | $747,000 | -82.2% | 100,000 | -69.0% | 0.00% | -50.0% |
| Q2 2019 | $4,191,000 | +360.0% | 322,848 | +331.5% | 0.00% | 0.0% |
| Q1 2019 | $911,000 | +6.9% | 74,816 | 0.0% | 0.00% | 0.0% |
| Q4 2018 | $852,000 | -25.3% | 74,816 | +42.5% | 0.00% | 0.0% |
| Q3 2018 | $1,140,000 | +16.4% | 52,516 | -5.2% | 0.00% | 0.0% |
| Q2 2018 | $979,000 | -16.6% | 55,405 | -0.7% | 0.00% | 0.0% |
| Q1 2018 | $1,174,000 | +3813.3% | 55,779 | +2556.1% | 0.00% | – |
| Q4 2017 | $30,000 | -95.5% | 2,100 | -94.9% | 0.00% | -100.0% |
| Q1 2017 | $664,000 | +1.2% | 40,863 | -6.1% | 0.00% | 0.0% |
| Q4 2016 | $656,000 | +82.2% | 43,500 | +84.3% | 0.00% | 0.0% |
| Q3 2016 | $360,000 | -80.3% | 23,600 | -50.0% | 0.00% | -50.0% |
| Q2 2016 | $1,832,000 | – | 47,200 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 700,000 | $42,833,000 | 8.57% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 308,819 | $18,897,000 | 7.82% |
| Vahanian & Associates Financial Planning Inc. | 45,533 | $2,786,000 | 6.44% |
| DCF Advisers, LLC | 238,500 | $14,594,000 | 6.39% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 50,956 | $20,930,000 | 4.72% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,531,923 | $93,738,000 | 2.86% |
| Nicholas Investment Partners, LP | 562,373 | $34,412,000 | 2.45% |
| Bellevue Group AG | 3,429,619 | $209,859,000 | 2.44% |
| WASATCH ADVISORS LP | 7,477,868 | $457,571,000 | 2.25% |
| Quantum Private Wealth, LLC | 73,772 | $4,514,000 | 1.95% |